雾化里克林诺酸可通过减弱巨细胞激活来缓解卵胺诱导的过敏喘
Longwei Yang1, Wenhao Ge2, Xi Lin1
1Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing 210094, China.
International immunopharmacology
|April 5, 2025
概括
酸 (Rios) 通过减少呼吸道炎症和保护肺部免受损伤,有效治疗过敏性喘. 这种八糖糖向巨细胞,为这种常见的呼吸系统疾病提供了潜在的新疗法.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 生物化学 生化学
背景情况:
- 过敏性喘的特征是气道炎症,主要是由巨细胞驱动的.
- 八糖 (Rios) 是一种八糖,在调节免疫反应方面表现出潜力.
- 乳腺细胞脱粒化是过敏喘病因的关键因素.
研究的目的:
- 在过敏性喘的小鼠模型中研究 nebulized Ricinoctaose (Rios) 的治疗效果.
- 为了确定里奥斯对气道过敏反应,炎症和肺病理学的影响.
- 阐明里奥斯的作用机制,特别是它与巨细胞的相互作用.
主要方法:
- 卵胺 (OVA) 诱导的过敏喘模型在小鼠中.
- 管理雾化里奥斯的管理.
- 评估气道过敏反应 (AHR),炎症细胞透,肺纤维化和粘液产生.
- 测量炎症性细胞因子,血清免疫球蛋白E (IgE) 和介质蛋白-4 (IL-4).
- 肺组织的H NMR代谢分析.
- 同焦激光显微镜 (CLM) 来追踪Rios.
- 使用RBL-2H3巨细胞进行体外研究.
主要成果:
- 在接受OVA治疗的小鼠中,雾化Rios显著降低了AHR,炎症细胞透,肺纤维化和粘液产生.
- 里奥斯抑制了肺炎性细胞因子的产生,并保护它免受OVA诱导的氧化损伤.
- 里奥斯减少了支气管洗液 (BALF) 中的中性粒细胞和巨细胞,并降低了血清IgE和IL-4水平.
- 1H NMR显示,里奥斯部分逆转了喘肺中的代谢变化.
- CLM证实里奥斯与乳腺细胞膜结合.
- 在体外,里奥斯抑制了巨细胞脱粒和炎症反应.
结论:
- 里奥斯对过敏性喘具有显著的治疗潜力.
- 该机制涉及调节巨细胞脱粒和媒介释放的机制.
- 里奥斯为管理过敏性喘提供了一个有前途的新疗法策略.
相关概念视频
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
186
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
186
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
160
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
160
01:19Antiasthma Drugs: Leukotriene Modifiers
180
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
180
01:20Asthma: Pathogenesis and Management
263
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
263
01:17Drugs Used in Lower Respiratory Disorders: Overview
284
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
284
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
160
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
160